| The University of British Columbia Patent applications |
| Patent application number | Title | Published |
|---|
| 20130122112 | Derivatized Hyperbranched Polyglycerols - Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C | 05-16-2013 |
| 20130115606 | SYSTEM AND METHOD FOR MICROFLUIDIC CELL CULTURE - Microfluidic devices and methods for perfusing a cell with perfusion fluid are provided herein, wherein the gravitational forces acting on the cell to keep the cell at or near a retainer or a retaining position exceed the hydrodynamic forces acting on the cell to move it toward an outlet. Also provided, are methods for assaying cell products within the microfluidic device. | 05-09-2013 |
| 20130096180 | Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same - Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. | 04-18-2013 |
| 20130092237 | ELECTROCHEMICAL PHOTOVOLTAIC CELLS - The invention provides a bio-photovoltaic device, in which a photoelectric center, exemplified by a biological photosynthetic reaction center (RC), is dispersed and mobile in a medium, such as an aqueous solution. The charges generated by the illuminated RC are transferred to electrodes via one or more mediators. In selected embodiments, the difference between the reaction rates of two types of mediator at the electrode surfaces, in conjunction with other charge transfer reaction equilibria, determines the direction of the photocurrent in the device. In an exemplified embodiment, the magnitude of the photocurrent is proportional to the incident light intensity, and the current increases nonlinearly with an increase in the RC concentration in the medium. | 04-18-2013 |
| 20130058938 | GNA11 MUTATIONS IN MELANOMA - The present invention provides methods of detecting mutations in a GNA11 gene in a melanocytic neoplasm for diagnostic and prognostic purposes. The invention further provides methods of treating such melanocytic neoplasm by modulating the activity of the mutated GNA11 gene. | 03-07-2013 |
| 20130045991 | NEUROPROTECTIVE MODULATION OF NMDA RECEPTOR SUBTYPE ACTIVITIES - In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity | 02-21-2013 |
| 20130045204 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 02-21-2013 |
| 20130017223 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS - A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties. | 01-17-2013 |
| 20120295265 | SYSTEMS AND METHODS FOR ENHANCED SCODA - Methods and apparatus for separating, concentrating and/or detecting molecules based on differences in binding affinity to a probe are provided. The molecules may be differentially modified. The molecules may be differentially methylated nucleic acids. The methods can be used in fields such as epigenetics or oncology to selectively concentrate or detect the presence of specific biomolecules or differentially modified biomolecules, to provide diagnostics for disorders such as fetal genetic disorders, to detect biomarkers in cancer, organ failure, disease states, infection or the like. | 11-22-2012 |
| 20120289820 | Apparatus And Method For Imaging A Medical Instrument - The invention provides an ultrasound imaging and medical instrument guiding apparatus, a system for acquiring and displaying ultrasound medical images and methods of using the apparatus and system in epidural anesthetic procedure. The apparatus comprises a hand-held ultrasound probe, configured to acquire a volumetric dataset representing a 3-D depiction of a volume; a mount to which the probe is mounted; and a medical instrument guide positionable relative to the ultrasound probe and configured to receive and guide a medical instrument along a propagation axis to a target in a body such that the target and the propagation axis intersect in the volume. The volumetric dataset acquired by the hand-held ultrasound probe comprises information about the medical instrument's position relative to the target in three dimensions and the medical instrument guide has a visible mark from which the depth of the medical instrument insertion along the propagation axis can be referenced. | 11-15-2012 |
| 20120279357 | LEACHING PROCESS FOR COPPER CONCENTRATES WITH A CARBON CATALYST - A method of recovering copper from a copper sulfide concentrate comprising a copper arsenic sulfosalt or a copper antimony sulfosalt, using carbon as a catalyst. The concentrate and carbon are added to an acidic sulfate leach solution. The copper is leached from the concentrate, in the presence of an oxygen-containing gas. The operating potential is maintained above a selected level. The carbon copper sulfide ratio of the carbon being added to the copper sulfide present in the concentrate being added is at least 1:20. The carbon may be maintained above a selected concentration in the leach solution. The leached copper is recovered from the solution by conventional methods. | 11-08-2012 |
| 20120276209 | NUCLEIC ACID-CONTAINING LIPID PARTICLES AND RELATED METHODS - Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles. | 11-01-2012 |
| 20120276207 | METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS - Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation. | 11-01-2012 |
| 20120264810 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES - Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject | 10-18-2012 |
| 20120237591 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES - Drug derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drug derivatized with a weak-base moiety that facilitates active loading of the drug through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drug to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drug derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drugs. | 09-20-2012 |
| 20120226265 | REMOTELY CONTROLLED DRUG DELIVERY SYSTEMS - Drug delivery devices responsive to at least one external stimulus are described, along with methods for their preparation and use. The devices can be configured to respond to the stimulus, providing “on demand” release of one or more deliverables such as pharmaceutical drugs. | 09-06-2012 |
| 20120225434 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS - The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject. | 09-06-2012 |
| 20120220646 | Treatment of Cancer by Inhibition of IGFBPs and Clusterin - Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide. | 08-30-2012 |
| 20120202873 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 08-09-2012 |
| 20120129925 | SHIP 1 MODULATORS - The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof. | 05-24-2012 |
| 20120114831 | HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES - Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%. | 05-10-2012 |
| 20120107321 | Antibodies And Epitopes Specific To Misfolded Prion Protein - The present invention relates to antibodies and immunogenic peptides specific to misfolded prion protein (PrP, e g, PrP | 05-03-2012 |
| 20120101166 | COMPOSITION AND METHOD FOR IRRIGATION OF A PREPARED DENTAL ROOT CANAL - Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection. | 04-26-2012 |
| 20120077861 | Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same - Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. | 03-29-2012 |
| 20120067796 | METHOD AND APPARATUS USING HYDROGEN PEROXIDE AND MICROWAVE SYSTEM FOR SLURRIES TREATMENT - A method and apparatus for treating slurries of organic solids is disclosed. A slurry of organic solids is admixed with hydrogen peroxide, followed by exposure to microwave irradiation resulting in the heating of the mixture and enhanced hydrolysis of the organic solids. The treated slurry of organic solids can then be further treated in a variety of downstream processes, including solid separation, digestion and fermentation. The supernatant portion of the treated slurry of organic solids can be a source from which to recover compounds such as nutrients (for example nitrogen, phosphate, potassium, magnesium, calcium) or industrial organic compounds (such as acetic acid, propionic acid, butyric acid), or as a source of readily biodegradable organic compounds for supplementing a biological wastewater treatment process, digester or fermenter. | 03-22-2012 |
| 20120067174 | PROCESSES FOR EXTRACTION OF NICKEL WITH IRON-COMPLEXING AGENT - The invention provides, in part, a process for extracting nickel from a source material including iron and nickel, by contacting the source material (e.g, an ultramafic ore) with an aqueous ammonia solution containing an iron-complexing agent (e.g., citrate) under suitable conditions, thereby extracting the nickel. The aqueous ammonia solution may optionally contain a sulfur-containing reductant, such as thiosulfate. | 03-22-2012 |
| 20110303839 | AP-ECD METHODS AND APPARATUS FOR MASS SPECTROMETRIC ANALYSIS OF PEPTIDES AND PROTEINS - An in-source atmospheric pressure electron capture dissociation (AP-ECD) method and apparatus for mass spectrometric analysis of peptides and proteins. An electrified sprayer generates a multiply-charged peptide/protein ions from a sample solution, a source of electrons for negative reagents, and a flow of gas for guiding positively charged ions from the electrified sprayer to a downstream reaction region within the guide. The reaction region being at or near atmospheric pressure and substantially free of the electric field from the electrified sprayer. In another embodiment, the method uses electron transfer dissociation (ETD), in the event that anions are substituted for electrons as the negative reagents. Fragment ions exiting the reaction region are subsequently passed into a mass analyzer of a mass spectrometer for mass analysis of the ions. | 12-15-2011 |
| 20110301451 | Apparatus And Method For Imaging A Medical Instrument - An ultrasound imaging and medical instrument guiding apparatus comprises: a first ultrasound probe configured to acquire a first volumetric dataset representing a 3-D image of a first volume; a second ultrasound probe configured to acquire a second volumetric dataset representing a 3-D image of a second volume; a mount to which the first and second probes are mounted, and a medical instrument guide. The first and second probes are located on the mount such that the first and second volumes overlap to form an overlapping volume. The medical instrument guide is positionable relative to the first and second ultrasound probes and is configured to receive and guide a medical instrument along a propagation axis to a target such that the target and the propagation axis intersect the overlapping volume. | 12-08-2011 |
| 20110269039 | APPARATUS AND METHOD FOR CONTROLLING VARIABLE POWER CONDITIONS IN A FUEL CELL - A fuel cell comprises an anode having an inner face and an outer face fluidly communicable with a fuel; a cathode having an inner face ionically communicable with and physically separated from the anode inner face, and having an outer face fluidly communicable with an oxidant; and at least one movable guard movable over at least one of the anode outer face, cathode outer face, anode inner face, and cathode inner face. The guard has a structure sufficient to block at least part of one or more of the anode's communication with the fuel, the cathode's communication with the oxidant, and the ionic communication between the anode and cathode thereby reducing a maximum potential active area of the fuel cell to an effective active area of the fuel cell. | 11-03-2011 |
| 20110263539 | SHIP 1 MODULATOR COMPOUNDS - The present invention provides the use of pelorol analogs of Formula, (I) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions. | 10-27-2011 |
| 20110256175 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 10-20-2011 |
| 20110229546 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS - A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided. | 09-22-2011 |
| 20110213010 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE - Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT. | 09-01-2011 |
| 20110196019 | Treatment of Cancer by Inhibition of IGFBPs and Clusterin - Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide. | 08-11-2011 |
| 20110190382 | Treatment of Cancer by Inhibition of IGFBPs and Clusterin - Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide. | 08-04-2011 |
| 20110189680 | Methods of Diagnosing Rejection of a Kidney Allograft Using Genomic or Proteomic Expression Profiling - A method of determining the acute allograft rejection status of a subject, the method comprising the steps of: determining the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the subject; comparing the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein the increase of the one or more than one nucleic acid markers is indicative of the acute rejection status of the subject. | 08-04-2011 |
| 20110189107 | ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF - Particular naturally occurring glycosylated acyl-flavonols, e.g. montbretin A (of the formula below wherein R | 08-04-2011 |
| 20110177130 | METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS - Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation. | 07-21-2011 |
| 20110171645 | METHODS OF DIAGNOSING ACUTE CARDIAC ALLOGRAFT REJECTION - The present invention relates to methods of diagnosing acute rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, metabolite profiling, or alloreactive T-cell genomic expression profiling, | 07-14-2011 |
| 20110152354 | Bispecific Oligonucleotide for the Treatment of CNS Malignancies - CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy. | 06-23-2011 |
| 20110150917 | Small Cationic Antimicrobial Peptides - Cationic bacteriocin and lantibiotic peptides are provided and their immunomodulatory activities are described. Methods are provided for selectively enhancing innate immunity. Other methods are provided for selectively suppressing a proinflammatory response. Other methods are provided for identifying a compound or compounds which modulate an innate immune response. Pharmaceutical compositions comprising the cationic bacteriocin and lantibiotic peptides or polynucleotides are also provided. | 06-23-2011 |
| 20110129566 | Functional Enhancement of Yeast to Minimize Production of Ethyl Carbamate Via Modified Transporter Expression - The invention provides a | 06-02-2011 |
| 20110117125 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 05-19-2011 |
| 20110104683 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME - The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. PAI-1 genotype screening may be useful in identifying patients who would benefit from increased monitoring by healthcare professionals, and/or possible therapeutic intervention, if the patient were to develop inflammation due to systemic inflammation response syndrome (SIRS), bacterial infection, bacteraemia, sepsis, septic shock, organ dysfunction, and trauma. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition. | 05-05-2011 |
| 20110100215 | Method and Apparatus for the Catalytic Reduction of Flue Gas NOx - Described herein are a method and a reactor for reducing NOx contained in a gaseous emission stream. The method and the reactor both utilize an adsorption region in which NOx is adsorbed by either a catalyst material or a non-catalytic adsorbent material and a reduction region in which the adsorbed NOx is catalytically reduced by a hydrocarbon stream. Concentrations of components that inhibit catalytic NOx reduction, such as water vapour, oxygen, and sulphur dioxide, are lower in the reduction region than in the adsorption region. By adsorbing NOx in the adsorption region of the reactor and reducing NOx in the reduction region of the reactor, the reactor and method described herein allow for the efficient reduction of NOx from the emission stream even when the emission stream has a relatively high concentration of components that can inhibit efficient NOx reduction. | 05-05-2011 |
| 20110056331 | LEACHING PROCESS FOR COPPER CONCENTRATES CONTAINING ARSENIC AND ANTIMONY COMPOUNDS - A method of recovering copper from a copper sulfide concentrate comprising a copper arsenic sulfosalt or a copper antimony sulfosalt, using pyrite as a catalyst. The concentrate and pyrite are added to an acidic sulfate leach solution. The copper is leached from the concentrate, in the presence of an oxygen-containing gas, under conditions whereby the pyrite is substantially unoxidized. The pyrite:copper sulfide ratio of the pyrite being added to the copper sulfide present in the concentrate being added is at least 1:3. The pyrite may be maintained at a concentration in the leach solution of at least 9 grams per liter. The leached copper is recovered from the solution by conventional methods. | 03-10-2011 |
| 20110054036 | COMPOSITION AND METHOD FOR IRRIGATION OF A PREPARED DENTAL ROOT CANAL - Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection. | 03-03-2011 |
| 20110053151 | MICROFLUIDIC DEVICE AND METHOD OF USING SAME - A microfluidic device comprising a plurality of reaction chambers in fluid communication with a flow channel formed in an elastomeric substrate, a vapor barrier for preventing evaporation from the plurality of reaction chambers, and a continuous phase fluid for isolation of each of the plurality of reaction chambers. | 03-03-2011 |
| 20110052573 | 14-3-3 ETA Antibodies and Uses Thereof for the Diagnosis and Treatment of Arthritis - The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided for the diagnosis and treatment of arthritis. | 03-03-2011 |
| 20110048950 | METHODS AND APPARATUS FOR PARTICLE INTRODUCTION AND RECOVERY - Particles may be injected into a matrix for concentration by scodaphoresis using a quadrupole injection field. Particles may be injected from two or more sample chambers simultaneously. Particle injection may be performed simultaneously with performing scodaphoresis. In some embodiments the particles are concentrated into a well containing fluid. The well can extend out of a plane of the matrix. Altering the relative phases of components of a scodaphoresis field permits concentration of selected particles and exclusion of other particles. Scodaphoresis methods may be applied to DNA, other bio-molecules and other particles. | 03-03-2011 |
| 20110042216 | SELF CONTAINED CAPILLARY ELECTROPHORESIS SYSTEM FOR INTERFACING WITH MASS SPECTROMETRY - A complete capillary electrophoresis (CE) system that is capable of providing a continuous flow of effluent at the exit of the flow-through outlet vial is provided. A self-contained capillary electrophoresis system with a flow-through outlet vial for interfacing with mass spectrometry includes a capillary having an upstream inlet end and a downstream terminus end; an electrically conductive hollow needle having an inner wall defining an internal tapered chamber, the internal tapered chamber dimensioned and configured to slidably accept the terminus end of the capillary, the capillary longitudinally inserted into and mounted within the internal tapered chamber to a distance whereby the terminus end of the capillary abuts the inner wall of the needle at the taper; and wherein a micro-reservoir is formed between the terminus end of the capillary and the downstream exit orifice. | 02-24-2011 |
| 20110021603 | TRPM-2 Antisense Therapy - It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed. | 01-27-2011 |
| 20110009472 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 01-13-2011 |
| 20110003339 | Pathogenic Escherichia Coli Associated Protein - The present invention provides a polypeptide, called EspA, which is secreted by pathogenic | 01-06-2011 |
| 20100324150 | HYPERBRANCHED POLYGLYCEROL FOR IMPROVING HEART FUNCTION - A method of improving heart function in a subject, the method comprising administering an effective amount of a hyperbranched polyglycerol to a subject. The improvement in heart function may include one or more of an increase in myocardial contractile function, reduced or absent fibrosis, an increase in mechanical efficiency of the heart, an increase in ejection fraction, an increase in glucose oxidation or a decrease in fatty acid oxidation, as determined by conventional methods known in the art. | 12-23-2010 |
| 20100324115 | Treatment of Squamous Cell Carcinoma with HSP27 Antisense Oligonucleotides and Radiotherapy - Squamous cell carcinomas, such as squamous head and neck cancer, are treated with a combination of radio-therapy and a therapeutic agent that reduces the amount of hsp27 in the squamous cancer cells. In specific embodiments, the therapeutic agent that reduces the amount of hsp27 is an antisense oligonucleotide therapeutic agent. | 12-23-2010 |
| 20100323990 | SHIP 1 MODULATOR PRODRUGS - The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions. | 12-23-2010 |
| 20100317038 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 12-16-2010 |
| 20100290692 | SYSTEMS AND METHODS FOR AUTOMATED CHARACTERIZATION OF GENETIC HETEROGENEITY IN TISSUE SAMPLES - Systems and methods for the quantitative automated analysis of pathology samples identify groups of spatially-associated similar cells. Cells may be identified as belonging to a group on the basis of spatial location and biomarkers. In some embodiments the biomarkers are multicolour fluorescence in situ hybridization (FISH) signals. Characteristics of the cells in a group may be combined to provide quantitative FISH results that may compensate for variations and artefacts such as thin sectioning that can result in the loss of information due to damage. In heterogeneous tissue samples, grouping cells can permit quantitative results regarding pathological cells to be extracted despite the presences of infiltrating non pathological cells. | 11-18-2010 |
| 20100267808 | Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same - Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. | 10-21-2010 |
| 20100254010 | ADAPTIVE SUNLIGHT REDIRECTOR - Longitudinally adjacent plane mirrors ( | 10-07-2010 |
| 20100199948 | Concurrent Injection Of Liquid And Gaseous Fuels In An Engine - Disclosed is a method and corresponding fuel injector for injecting gaseous and liquid fuel into an engine. The method comprises delivering a liquid fuel to a fuel injector, delivering a pressurized gaseous fuel to the fuel injector, entraining the liquid fuel within the gaseous fuel within a chamber of the fuel injector and injecting the gaseous fuel and atomized liquid fuel into the combustion chamber. The liquid fuel can be passed through and dispensed from a needle into a chamber in the injector nozzle where it is entrained in the gaseous fuel during an injection event. The liquid/gas mass ratio is controlled by the needle movement, hydraulic resistances or electronic valves so that the majority of the liquid is injected during the first part of the gas injection. The injector can be used for late cycle direct injection of natural gas, or any number of gaseous fuel blends combined with many liquid fuels such as diesel, biodiesel and DME. | 08-12-2010 |
| 20100198562 | STRIPWISE CONSTRUCTION OF 3D CURVED SURFACES - A 3D structure approximating a 3D curved surface having non-zero Gaussian curvature over a portion of the surface. The structure is formed of a plurality of thin strips ( | 08-05-2010 |
| 20100198345 | CALCIUM PHOSPHATE COATED IMPLANTABLE MEDICAL DEVICES, AND ELECTROPHORETIC DEPOSITION PROCESSES FOR MAKING SAME - This invention relates to novel calcium phosphate coated implantable medical devices, and electrophoretic deposition processes for making same. A process of coating an implantable medical device with a calcium phosphate coating comprising: (a) pretreating a substrate with an alkaline solution; (b) preparing a slurry comprising a solvent and a defined size range of calcium phosphate particles; (c) immersing the pretreated substrate in the slurry; and (d) coating the calcium phosphate particles onto the pretreated substrate by electrophoretic deposition. | 08-05-2010 |
| 20100178588 | FABRICATING SOLID OXIDE FUEL CELLS - A method for making a solid oxide fuel cell component includes depositing a cathode material directly onto a metallic interconnect. The interconnect may comprise stainless steel or another suitable metal. The cathode material may comprise a ceramic. Examples of cathode materials are yttria-stabilized zirconia (YSZ) and mixtures of YSZ with other ceramics such as lanthanum strontium manganate. The cathode material may be deposited by plasma spraying. A pore former may be plasma sprayed together with the cathode material to provide a porous cathode. Electrolyte and anode materials may be deposited on the cathode material also by plasma spraying. Plasma conditions may be selected to provide a dense electrolyte layer. | 07-15-2010 |
| 20100174356 | STENT GRAFTS WITH BIOACTIVE COATINGS - Stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the in vivo adhesion of the stent graft to vessel walls, or, otherwise induces or accelerates an in vivo fibrotic reaction causing said stent graft to adhere to vessel wall. Also provided are methods for making and using such stent grafts. | 07-08-2010 |
| 20100160451 | METHODS AND COMPOSITIONS FOR CONTROL OF CABBAGE LOOPER, Trichoplusia ni - The invention provides in part dialkoxybenzene compounds for controlling infestation by a | 06-24-2010 |
| 20100151354 | Membraneless Fuel Cell And Method Of Operating Same - A direct fuel cell comprises a cathode comprising electroactive catalyst material; and an anode assembly comprising an anode having a porous layer and electroactive catalyst material in the porous layer. The electrode characteristics of the anode assembly are selected so that fuel supplied to the anode is reacted within the anode so that cross-over from the anode to the cathode does not have more than a 10% negative effect on voltage or a 25 mV voltage loss when at peak power and steady state conditions. The anode and cathode each have a first major surface facing each other in non-electrical contact and without a microporous separator or ion exchange membrane therebetween. | 06-17-2010 |
| 20100150826 | MICROPOROUS METALS AND METHODS FOR HYDROGEN GENERATION FROM WATER SPLIT REACTION - The present invention relates to hydrogen generating microporous metals, methods for preparing microporous metals, and methods for producing hydrogen from water using the metals and systems of the invention. In particular, microporous metals selected from the group comprising aluminum (Al), magnesium (Mg), silicon (Si), Iron (Fe) and zinc (Zn), capable of producing hydrogen upon reaction of the metal with water having a neutral pH are provided. Methods for preparing microporous metals comprising the steps of selecting a metal that is sufficiently electropositive (i.e. water reactive); and introducing microporosity in the selected metal by means of mechanical deformation, or metallurgical techniques, in order to generate the microporous metal are also provided, as is a method for producing hydrogen comprising reacting a microporous metal powder with water at a pH of between 4 and 10. | 06-17-2010 |
| 20100128340 | BRIGHTNESS ENHANCEMENT BY FLUID INTERFACE DEFORMATION IN TIR-MODULATED DISPLAYS - A reflective display having a plurality of transparent hemi-beads ( | 05-27-2010 |
| 20100092842 | DENSIFIED CERAMIC MATERIALS AND RELATED METHODS - A method for making a densified ceramic layer comprises plasma spraying a layer of the ceramic onto a substrate; spin-coating the plasma-sprayed layer with a sol, and firing the spin-coated ceramic layer. The method may be applied in producing layers of yttria stabilized zirconia (YSZ) having application as electrolyte layers for solid oxide fuel cells or thermal barrier coatings, for example. The firing may be performed at a relatively low temperature such as 650° C. or even below. A method for enhancing electrochemical properties of an interface involving a layer of YSZ or other ceramic comprises spin-coating or otherwise impregnating the layer with a sol and heating the spin-coated layer. | 04-15-2010 |
| 20100085627 | MICROLENS-ASSISTED BRIGHTNESS ENHANCEMENT IN REFLECTIVE IMAGE DISPLAYS - A reflective display having a light reflector ( | 04-08-2010 |
| 20100048709 | Treatment of Prostate Cancer with DDC Inhibitor - Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer. | 02-25-2010 |
| 20100048653 | NEUROPROTECTIVE MODULATION OF NMDA RECEPTOR SUBTYPE ACTIVITIES - In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity | 02-25-2010 |
| 20100047134 | FLUIDIZED BED WASTEWATER TREATMENT APPARATUS - A fluidized bed reactor for removing phosphorus and nitrogen from wastewater has a column comprising a number of sections. The diameter of the column changes stepwise between the sections. A flow velocity in excess of 100 cm/min is maintained in a lowermost one of the sections and lower flow velocities are maintained in subsequent sections. A struvite supersaturation ratio is controlled in part by recycling wastewater from an outlet of the column. Struvite pellets are removed periodically from the bottom of the column. | 02-25-2010 |
| 20100044306 | METHOD AND APPARATUS USING HYDROGEN PEROXIDE AND MICROWAVE SYSTEM FOR SLURRIES TREATMENT - A method and apparatus for treating slurries of organic solids is disclosed. A slurry of organic solids is admixed with hydrogen peroxide, followed by exposure to microwave irradiation resulting in the heating of the mixture and enhanced hydrolysis of the organic solids. The treated slurry of organic solids can then be further treated in a variety of downstream processes, including solid separation, digestion and fermentation. The supernatant portion of the treated slurry of organic solids can be a source from which to recover compounds such as nutrients (for example nitrogen, phosphate, potassium, magnesium, calcium) or industrial organic compounds (such as acetic acid, propionic acid, butyric acid), or as a source of readily biodegradable organic compounds for supplementing a biological wastewater treatment process, digester or fermenter. | 02-25-2010 |
| 20100041631 | METHODS AND AGENTS FOR TREATING TUBERCULOSIS - The present invention relates to the treatment of tuberculosis (mycobacterial infections) by the use of KshAB complex inhibitors, or a KstD molecule, or a HsaAB complex, or a HsaC molecule, or a HsaD molecule. The application also includes a method for identifying an inhibitor or modulator of the previously mentioned molecules and complexes. | 02-18-2010 |
| 20100041152 | METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS - Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable. | 02-18-2010 |
| 20090298711 | VASOPRESSIN PATHWAY POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS - The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with one or more vasopressin receptor agonists to identify subjects having a greater benefit from treatment with vasopressin receptor agonist(s). The method generally comprises determining a vasopressin pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response genotype to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with a vasopressin receptor agonist and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with vasopressin receptor agonists based on the subject's genotype. | 12-03-2009 |
| 20090292008 | Compositions and Methods for Treatment of Prostate and Other Cancers - Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form. | 11-26-2009 |
| 20090281166 | Treatment of Cancer by Inhibition of HSP27 - A cancer is evaluated for selection of appropriate therapy by evaluating a sample of cancerous tissue to determine an expression of level of phosphatase and tensin homologue deleted from chromosome 10 (PTEN); and in the case where the expression level of functional PTEN is below a threshold level, identifying the cancer as susceptible to an active agent that inhibits the expression of heat shock protein 27 (hsp27). The evaluation may be included as part of a method of treatment, in which an hsp27 inhibitor is selected as a therapeutic agent when the PTEN level is below the threshold. | 11-12-2009 |
| 20090264487 | HEMIASTERLIN ANALOGS - This invention provides analogs of hemiasterlin, methods of synthesis of the analogs and use of the analogs as a cytotoxic anti-mitotic agents. | 10-22-2009 |
| 20090262414 | IONIC ELECTROPHORESIS IN TIR-MODULATED REFLECTIVE IMAGE DISPLAYS - A reflective display having a plurality of transparent hemi-beads ( | 10-22-2009 |
| 20090258089 | Chemo- and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides - Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents. | 10-15-2009 |
| 20090257981 | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same - Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies. | 10-15-2009 |
| 20090221678 | Compositions and Methods for Treatment of Prostate and Other Cancers - Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form. | 09-03-2009 |
| 20090148458 | COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION OF SUBJECT OUTCOME AND RESPONSE TO THERAPY - The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition or hypertension. The method generally comprises determining a coagulation factor III genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. The invention also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype. | 06-11-2009 |
| 20090146582 | Colour rendering in compact fluorescent lamps - Compact fluorescent lamps (CFLs) are characterized by impaired colour rendering, due to their low illumination capability near the blood-red edge of the visible spectrum. Red light output by a light emitting diode (LED) has a relatively narrow spectral distribution, and LEDs are able to produce red light with reasonable efficiency. Blending the light output of a CFL with a small amount of blood-red light emitted by one or more inexpensive LEDs improves colour rendering, while reducing the overall energy cost of operating the CFL-LED hybrid lamp. | 06-11-2009 |
| 20090143679 | METHOD AND APPARATUS FOR IMAGING THE MECHANICAL PROPERTIES OF TISSUE FROM AN ENDOCAVITY - The present invention relates to a method and apparatus for imaging the mechanical properties of a tissue region from within an endocavity of a patient. The apparatus generally comprises an ultrasound probe, a vibration assembly translationally coupled to probe and operable to vibrate the probe along a vibration plane, and a rotation assembly rotationally coupled to the vibration assembly and operable to rotate the probe and vibration assembly about a selected rotational range. The method generally comprises inserting an ultrasound probe into an endocavity of a patient, vibrating the probe along a vibration plane thereby causing deformational excitement of a tissue region contacted by the probe, capturing a first series of ultrasound images of the tissue region, rotating the vibration plane relative to the tissue region by a selected angular rotation, and capturing a second series of ultrasound images of the tissue region. | 06-04-2009 |
| 20090139867 | SCODAPHORESIS AND METHODS AND APPARATUS FOR MOVING AND CONCENTRATING PARTICLES - Methods and apparatus for moving and concentrating particles apply an alternating driving field and an alternating field that alters mobility of the particles. The driving field and mobility-varying field are correlated with one another. The methods and apparatus may be used to concentrate DNA or RNA in a medium, for example. Methods and apparatus for extracting particles from one medium into another involve applying an alternating driving field that causes net drift of the particles from the first medium into the second medium but no net drift of the particles in the second medium. | 06-04-2009 |
| 20090136108 | METHOD FOR AUTOMATED DELINEATION OF CONTOURS OF TISSUE IN MEDICAL IMAGES - The present invention relates to a method for delineating the contour of an object in captured medical images by first transforming the shape of the object into a simple geometric shape that is more computationally tractable than the shape of the object. After the contour of the transformed shape is detected, the inverse of the transformation is applied to the contour such that it represents the contour of the object in the captured medical image. | 05-28-2009 |
| 20090120795 | Apparatus And Methods For Concentrating And Separating Particles Such As Molecules - Particles of interest, such as DNA molecules, are injected into a medium by applying a first field. Once in the medium the particles are concentrated by applying one or more fields that cause mobilities of the particles in the medium to vary in a manner that is correlated with motions of the particles. Particle injection and particle concentration may be performed concurrently or in alternation. | 05-14-2009 |
| 20090105351 | MICELLAR DRUG DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS - This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient. | 04-23-2009 |
| 20090088573 | BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE - This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, | 04-02-2009 |
| 20090046037 | HIGH RESOLUTION DISPLAY OF 3D IMAGES - A 3D display has a backlight, image panel, lens array, and aperture mask. The lens array has a plurality of converging lenses having optical axes perpendicular to the image panel. The aperture mask has a plurality of electro-optic elements. Each element is aligned closely proximate to a corresponding one of the lenses and is selectably switchable between “on” to permit passage of light rays through the element, or “off” to prevent passage of light rays through the element. The elements are arranged in subsets of adjacent elements. A controller electronically coupled to the image panel and to the aperture mask repetitively selects an electro-optic element in each subset, switches the selected elements “on”, switches all other elements in each subset “off”, and applies to the image panel a selected plurality of representations of an image, each representation corresponding to a plurality of different viewing directions of the image. | 02-19-2009 |
| 20090042868 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitors - Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure. | 02-12-2009 |
| 20090030638 | SELF-CALIBRATION METHOD AND APPARATUS FOR ON-AXIS ROTARY ENCODERS - A self-calibration method and apparatus for on-axis rotary encoders comprising the steps of: receiving output signals from a detector during a spindle-free response period, the signals including a plurality of data sets wherein each data set comprises the periods between sampling events occurring in one revolution of the encoder at an angular speed, selecting a data set pair from the output signals, wherein the data set pair contains two linearly uncorrelated data sets; defining a model of the angular distances between each sampling event occurring in one revolution of the encoder as a function of one or more damping coefficients and the periods between each sampling event as contained in the data set pair; solving the model for the angular distances for the data set pair using circular closure and dynamic reversal techniques; and establishing an encoder error map using the selected solved angular distances from the model. | 01-29-2009 |
| 20090005300 | Antimicrobial Peptides and Methods of Use - Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V | 01-01-2009 |
| 20080317665 | COMPOSITIONS AND METHODS FOR GENERATING HYDROGEN FROM WATER - The present invention relates to methods, compositions and systems for producing hydrogen from water involving reacting metal particles with water in the presence of an effective amount of catalyst. In particular the invention pertains to methods, compositions and systems for producing hydrogen upon reaction of metal particles selected from the group consisting of aluminum (Al), magnesium (Mg), silicon (Si) and zinc (Zn) with water, in the presence of an effective amount of a catalyst, wherein the catalyst is a water-soluble inorganic salt. | 12-25-2008 |
| 20080313175 | METHOD AND SYSTEM FOR INTERACTION-BASED EXPERTISE REPORTING - A task-based method and system for expertise reporting provides a display of a knowledge worker's expertise in structured documents based on their access and use of those documents. | 12-18-2008 |
| 20080300807 | Electric Winding Displacement Detection Method and Apparatus - A method and system for obtaining the characteristic impedance of an electrical winding by measuring the input and output voltages and the currents within a winding across a low frequency range, and applying transmission line properties to model the winding. The characteristic impedance (Zc) is directly proportional to the capacitance of the winding, and is independent of external circuits. Thus any changes to Zc will reflect movements of the winding that would affect the capacitance. Because Zc has a smooth and robust monotonical relationship with frequency of the applied signal, the resulting curve is exponential in shape. A relative comparison between Zc curves will provide a clear indication of the overall axial or radial winding movements, or winding faults, which can be used to assess the overall health of the winding. | 12-04-2008 |
| 20080291362 | Diffuser for Light From Light Source Array and Displays Incorporating Same - An optical structure placeable between a backlight array of point light sources and a planar display. The structure distributes light emitted by the point light sources to uniformly illuminate the plane of the display, without introducing significant viewing parallax. The emitted light is partially collimated within a preferred angular viewing range, maximizing the display's luminance when viewed from the normal direction. The structure is highly reflective, such that a substantial portion of any non-emitted light rays are internally reflected by the structure, increasing the likelihood that those rays will be subsequently emitted by the structure. | 11-27-2008 |
| 20080280189 | Fabrication of Electrode Structures by Thermal Spraying - A method for the rapid production of electrode structures such as Cu-SDC anodes for use in direct oxidation solid oxide fuel cells involves co-depositing a copper-containing material and a ceramic by plasma spraying to form a coating on a substrate. Layers of CuO-SDC have been co-deposited by air plasma spraying, followed by in-situ reduction of the CuO to Cu in the anodes. Materials having catalytic properties, such as cobalt, may also be incorporated in the structures. Controlled compositional or microstructural gradients may be applied to optimize the microstructure and composition of the coatings. | 11-13-2008 |
| 20080274996 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 11-06-2008 |
| 20080261912 | Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same - Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. | 10-23-2008 |
| 20080258137 | Thin Film Field Effect Transistors Having Schottky Gate-Channel Junctions - An active electronic device has drain and source electrodes that make ohmic conduct with a layer of a semiconductor. The semiconductor layer may be a thin layer of an organic or amorphous semiconductor. The drain and source electrodes are on a first face of the layer of semiconductor at locations that are spaced apart on either side of a channel. The device has a gate electrode on a second face of the layer of semiconductor adjacent to the channel. The gate electrode makes a Schottky contact with the semiconductor to produce a depletion region in the channel. The gate electrode may encapsulate the channel so that the channel is protected from contact with oxygen, water molecules or other materials in the environment. In some embodiments, the device has an additional gate electrode separated from the semiconductor layer by an insulating layer. Such embodiments combine features of OFETs and MESFETs. | 10-23-2008 |
| 20080257826 | Fluidized Bed Wastewater Treatment - A fluidized bed reactor ( | 10-23-2008 |
| 20080255090 | Ceratamines A and B, and Analogues, Syntheses and Pharmaceutical Compositions Thereof - Antimitotic compounds and salts are provided in which the compound has the structure (formula (I)): wherein X and Y are substituted or unsubstituted and are selected from carbon atoms and atoms of groups 15 and 16 of the periodic table; Z is selected from N—R, O and S; U is selected from CR | 10-16-2008 |
| 20080204342 | Reflector Antenna - A reflector antenna includes a feed configured to always point during operation in a direction that opposes ingress of water into the feed, and a reflector having a truncated spherical reflecting surface, wherein a relative orientation of the reflector and the feed is adjustable. Another reflector antenna includes a feed configured to always point during operation in a direction that opposes ingress of water into the feed, and a reflector spaced apart from the feed by a focal length at least as great as a diameter of the reflector. Another reflector antenna includes a feed and a reflector having a truncated spherical reflecting surface, wherein the reflector is spaced apart from the feed by a focal length at least as great as a diameter of the reflector. | 08-28-2008 |
| 20080200417 | HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES - Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%. | 08-21-2008 |
